Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Apricus Biosciences Announces Completion of Transfer of the Marketing Authorizations for Vitaros® in Finland and Denmark to Ferring Pharmaceuticals
Ferring Demonstrates Continued Progress Towards Building the Vitaros Brand in Europe 
From GlobeNewswire News Releases
Drug Makers Stocks Technical Reports -- Pernix Therapeutics, Synergy Pharma, Novo Nordisk, and Apricus Biosciences
From PR Newswire
Top Performing Industries For September 14, 2016
At 10:30 am, the Dow rose 0.48 percent to 18,153.83, the broader Standard & Poor's 500 index moved up 0.56 percent to ... 
Tags Markets Intraday Update AAPL
From Benzinga
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina
First Vitaros Approval in Latin America, Registrations Also Filed in Mexico and Colombia 
From GlobeNewswire News Releases
Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will... 
From GlobeNewswire News Releases
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati
To be Commercialized in Portugal and Ireland as Vitaros® and in Poland as Vytaros® 
From GlobeNewswire News Releases
BRIEF-Apricus Biosciences says gets $4.5 mln in upfront payments from Ferring
* Company's partner in United Kingdom, has received United Kingdom marketing authorization for Vitaros 
Tags companyNews
From Reuters: Company News
Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to Ferring Pharmaceuticals
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company’s new partner... 
From GlobeNewswire News Releases
Apricus Biosciences Announces Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company’s new partner... 
From GlobeNewswire News Releases
18 Biggest Mid-Day Losers For Friday
Computer Programs & Systems, Inc. (NASDAQ: CPSI) tumbled 30 percent to $27.36 after the company posted ... 
Tags BMY News Benzinga
From Benzinga
Worst Performing Industries For August 5, 2016
The Dow rose 0.75 percent to 18,490.22, while the NASDAQ composite index gained 0.99 percent to 5,217.26. The broader Standard ... 
Tags News MCZ APRI
From Benzinga
Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the second quarter of 2016 and... 
From GlobeNewswire News Releases
Apricus Biosciences to Present at the Canaccord Genuity 36th Annual Growth Conference
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will... 
From GlobeNewswire News Releases
Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2016 financial results... 
From GlobeNewswire News Releases
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Republic of Lebanon Ministry of Public Health... 
From GlobeNewswire News Releases
BRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals
* Apricus biosciences inc says apricus and sandoz agree to mutually terminate license agreement 
Tags companyNews
From Reuters: Company News
Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has further expanded its exclusive distribution... 
From GlobeNewswire News Releases
BRIEF-Apricus Biosciences enters into common stock purchase agreement with Aspire Capital
* Apricus Biosciences enters into common stock purchase agreement with Aspire Capital 
Tags companyNews
From Reuters: Company News
Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
$7.0 Million Equity Facility with Existing Long-Term Shareholder 
From GlobeNewswire News Releases
BRIEF-Apricus Biosciences reports Q1 loss per share of $0.05
* To continue to reduce operating expenses with goal of achieving reductions of about 30% in 2016, 60% in 2017 compared to 2015 
Tags companyNews
From Reuters: Company News
Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
Vitaros® U.S. NDA Re-Submission on Schedule for 3Q 2016 
From GlobeNewswire News Releases
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros® and erectile dysfunction (“ED”)... 
From GlobeNewswire News Releases
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros® and erectile dysfunction (“ED”)... 
From GlobeNewswire News Releases
Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2016 financial results... 
From GlobeNewswire News Releases
Apricus Biosciences Updates Strategic Corporate Objectives
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, updated its strategic objectives today to include its plans to... 
From GlobeNewswire News Releases
Stocks Hitting 52-Week Lows
Cellectar Biosciences Inc (NASDAQ: CLRB) shares fell 7.75 percent to touch a new 52-week low of $3.25. Cellectar Biosciences shares ... 
Tags Markets Intraday Update CLRB
From Benzinga
Apricus Biosciences reports disappointing results
Apricus Biosciences Inc. (Nasdaq: APRI) reported disappointing results from a Phase 2b study of fispermifene to treat symptomatic secondary hypogonadism sending the stock price plummeting 64 cents to... 
From MarketMinute.com Stock News
Mid-Afternoon Market Update: Dow Jumps 50 Points; Pandora Shares Slide
Toward the end of trading Monday, the Dow traded up 0.29 percent to 17,566.31 while the NASDAQ gained 0.09 percent to 4,777.83. The ... 
Tags P ACAD Intraday Update
From Benzinga
Apricus Biosciences Plunges 50% Following 'Disappointing' Phase 2B Data
Shares of Apricus Biosciences Inc (NASDAQ: APRI) plunged more than 50 percent on Monday after the company disclosed ... 
Tags News apricus biosciences Fispemifene
From Benzinga
Mid-Day Market Update: Qlik Technologies Surges Amid Potential Sale; VirtualScopics Shares Decline
Midway through trading Monday, the Dow traded down 0.09 percent to 17,500.19 while the NASDAQ declined 0.20 percent to 4,763.90. The ... 
Tags News Mid/Day Market Update CALM
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.